A Randomised Comparison of Daily 25 mg Versus 5 mg Lenalidomide as Maintenance Therapy After High-Dose Therapy and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma.
Phase of Trial: Phase III
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms LenaMain
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 17 Jan 2018 Status changed from active, no longer recruiting to completed.
- 05 Sep 2017 Planned End Date changed from 1 Dec 2016 to 31 Dec 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History